Literature DB >> 25331118

Functional factor XIII-A is exposed on the stimulated platelet surface.

Joanne L Mitchell1, Ausra S Lionikiene1, Steven R Fraser1, Claire S Whyte1, Nuala A Booth1, Nicola J Mutch1.   

Abstract

Factor XIII (FXIII) stabilizes thrombi against fibrinolysis by cross-linking α2-antiplasmin (α2AP) to fibrin. Cellular FXIII (FXIII-A) is abundant in platelets, but the extracellular functions of this pool are unclear because it is not released by classical secretion mechanisms. We examined the function of platelet FXIII-A using Chandler model thrombi formed from FXIII-depleted plasma. Platelets stabilized FXIII-depleted thrombi in a transglutaminase-dependent manner. FXIII-A activity on activated platelets was unstable and was rapidly lost over 1 hour. Inhibiting platelet activation abrogated the ability of platelets to stabilize thrombi. Incorporating a neutralizing antibody to α2AP into FXIII-depleted thrombi revealed that the stabilizing effect of platelet FXIII-A on lysis was α2AP dependent. Platelet FXIII-A activity and antigen were associated with the cytoplasm and membrane fraction of unstimulated platelets, and these fractions were functional in stabilizing FXIII-depleted thrombi against lysis. Fluorescence confocal microscopy and flow cytometry revealed exposure of FXIII-A on activated membranes, with maximal signal detected with thrombin and collagen stimulation. FXIII-A was evident in protruding caps on the surface of phosphatidylserine-positive platelets. Our data show a functional role for platelet FXIII-A through exposure on the activated platelet membrane where it exerts antifibrinolytic function by cross-linking α2AP to fibrin.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25331118      PMCID: PMC4309449          DOI: 10.1182/blood-2014-06-583070

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  75 in total

1.  Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention.

Authors:  J P Collet; G Montalescot; C Lesty; Z Mishal; J Soria; R Choussat; G Drobinski; C Soria; P Pinton; P Barragan; D Thomas
Journal:  Circulation       Date:  2001-05-15       Impact factor: 29.690

2.  Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin.

Authors:  M L Schwartz; S V Pizzo; R L Hill; P A McKee
Journal:  J Biol Chem       Date:  1973-02-25       Impact factor: 5.157

3.  Subunit structure of human fibrinogen, soluble fibrin, and cross-linked insoluble fibrin.

Authors:  P A McKee; P Mattock; R L Hill
Journal:  Proc Natl Acad Sci U S A       Date:  1970-07       Impact factor: 11.205

4.  Clot retraction is mediated by factor XIII-dependent fibrin-αIIbβ3-myosin axis in platelet sphingomyelin-rich membrane rafts.

Authors:  Kohji Kasahara; Mizuho Kaneda; Toshiaki Miki; Kazuko Iida; Naoko Sekino-Suzuki; Ikuo Kawashima; Hidenori Suzuki; Motoyuki Shimonaka; Morio Arai; Yoshiko Ohno-Iwashita; Soichi Kojima; Mitsuhiro Abe; Toshihide Kobayashi; Toshiro Okazaki; Masayoshi Souri; Akitada Ichinose; Naomasa Yamamoto
Journal:  Blood       Date:  2013-09-03       Impact factor: 22.113

5.  Catalytic life of activated factor XIII in thrombi. Implications for fibrinolytic resistance and thrombus aging.

Authors:  B R Robinson; A K Houng; G L Reed
Journal:  Circulation       Date:  2000-09-05       Impact factor: 29.690

6.  Factor XIII in human plasma and platelets.

Authors:  J McDonagh; R P McDonagh; J M Delâge; R H Wagner
Journal:  J Clin Invest       Date:  1969-05       Impact factor: 14.808

7.  New insights into the expression and role of platelet factor XIII-A.

Authors:  A Jayo; I Conde; P Lastres; V Jiménez-Yuste; C González-Manchón
Journal:  J Thromb Haemost       Date:  2009-04-24       Impact factor: 5.824

8.  Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.

Authors:  G L Reed; G R Matsueda; E Haber
Journal:  Thromb Haemost       Date:  1992-09-07       Impact factor: 5.249

9.  Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice.

Authors:  Masayoshi Souri; Shiori Koseki-Kuno; Naoki Takeda; Jay L Degen; Akitada Ichinose
Journal:  Int J Hematol       Date:  2007-12-05       Impact factor: 2.490

10.  Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis.

Authors:  N J Mutch; J S Koikkalainen; S R Fraser; K M Duthie; M Griffin; J Mitchell; H G Watson; N A Booth
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

View more
  40 in total

1.  Coated platelets function in platelet-dependent fibrin formation via integrin αIIbβ3 and transglutaminase factor XIII.

Authors:  Nadine J A Mattheij; Frauke Swieringa; Tom G Mastenbroek; Michelle A Berny-Lang; Frauke May; Constance C F M J Baaten; Paola E J van der Meijden; Yvonne M C Henskens; Erik A M Beckers; Dennis P L Suylen; Marc W Nolte; Tilman M Hackeng; Owen J T McCarty; Johan W M Heemskerk; Judith M E M Cosemans
Journal:  Haematologica       Date:  2015-12-31       Impact factor: 9.941

2.  Coagulation factor XIIIa is inactivated by plasmin.

Authors:  Woosuk S Hur; Nima Mazinani; X J David Lu; Heidi M Britton; James R Byrnes; Alisa S Wolberg; Christian J Kastrup
Journal:  Blood       Date:  2015-09-10       Impact factor: 22.113

Review 3.  Newly-Recognized Roles of Factor XIII in Thrombosis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

4.  Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system.

Authors:  Yuko Suzuki; Hideto Sano; Liina Mochizuki; Naoki Honkura; Tetsumei Urano
Journal:  Blood Adv       Date:  2020-11-10

5.  Temporal contribution of the platelet body and balloon to thrombin generation.

Authors:  Ejaife O Agbani; Ingeborg Hers; Alastair W Poole
Journal:  Haematologica       Date:  2017-07-13       Impact factor: 9.941

Review 6.  Fibrinogen, red blood cells, and factor XIII in venous thrombosis.

Authors:  B L Walton; J R Byrnes; A S Wolberg
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

Review 7.  Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Eur J Med Chem       Date:  2020-05-18       Impact factor: 6.514

8.  Proteolytic and nonproteolytic activation mechanisms result in conformationally and functionally different forms of coagulation factor XIII A.

Authors:  Boris A Anokhin; William L Dean; Kerrie A Smith; Matthew J Flick; Robert A S Ariëns; Helen Philippou; Muriel C Maurer
Journal:  FEBS J       Date:  2019-08-28       Impact factor: 5.542

9.  Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity.

Authors:  Joanne L Mitchell; Ausra S Lionikiene; Georgi Georgiev; Anja Klemmer; Chelsea Brain; Paul Y Kim; Nicola J Mutch
Journal:  Blood       Date:  2016-09-30       Impact factor: 22.113

10.  Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.

Authors:  H M H Spronk; T Padro; J E Siland; J H Prochaska; J Winters; A C van der Wal; J J Posthuma; G Lowe; E d'Alessandro; P Wenzel; D M Coenen; P H Reitsma; W Ruf; R H van Gorp; R R Koenen; T Vajen; N A Alshaikh; A S Wolberg; F L Macrae; N Asquith; J Heemskerk; A Heinzmann; M Moorlag; N Mackman; P van der Meijden; J C M Meijers; M Heestermans; T Renné; S Dólleman; W Chayouâ; R A S Ariëns; C C Baaten; M Nagy; A Kuliopulos; J J Posma; P Harrison; M J Vries; H J G M Crijns; E A M P Dudink; H R Buller; Y M C Henskens; A Själander; S Zwaveling; O Erküner; J W Eikelboom; A Gulpen; F E C M Peeters; J Douxfils; R H Olie; T Baglin; A Leader; U Schotten; B Scaf; H M M van Beusekom; L O Mosnier; L van der Vorm; P Declerck; M Visser; D W J Dippel; V J Strijbis; K Pertiwi; A J Ten Cate-Hoek; H Ten Cate
Journal:  Thromb Haemost       Date:  2018-01-29       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.